156 related articles for article (PubMed ID: 36402940)
21. Economic burden of joint analysis in psoriasis: US claims analysis.
Prince P; Skornicki M; Suruki R; Lee E; Louder A
Am J Manag Care; 2021 Dec; 27(12):e406-e412. PubMed ID: 34889582
[TBL] [Abstract][Full Text] [Related]
22. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020.
Merola JF; Dennis N; Chakravarty SD; Villacorta R; Mesana L; Lin I; Wang Y; Shawi M; Pacou M; Baker T; Peterson S
Clin Rheumatol; 2021 Oct; 40(10):4061-4070. PubMed ID: 33934270
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
[TBL] [Abstract][Full Text] [Related]
24. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
Cai B; Said Q; Li X; Li FY; Arcona S
J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
[No Abstract] [Full Text] [Related]
25. Economic Burden among Patients with Vitiligo in the United States: A Retrospective Database Claims Study.
Ezzedine K; Soliman AM; Li C; Camp HS; Pandya AG
J Invest Dermatol; 2024 Mar; 144(3):540-546.e1. PubMed ID: 37739338
[TBL] [Abstract][Full Text] [Related]
26. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
[TBL] [Abstract][Full Text] [Related]
27. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
[TBL] [Abstract][Full Text] [Related]
28. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
[TBL] [Abstract][Full Text] [Related]
29. Real-world burden of comorbidities in US patients with psoriasis.
Shah K; Mellars L; Changolkar A; Feldman SR
J Am Acad Dermatol; 2017 Aug; 77(2):287-292.e4. PubMed ID: 28623046
[TBL] [Abstract][Full Text] [Related]
30. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data.
Pisc J; Ting A; Skornicki M; Sinno O; Lee E
J Comp Eff Res; 2024 Jan; 13(1):e230108. PubMed ID: 38099519
[No Abstract] [Full Text] [Related]
31. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
Schwab P; Dhamane AD; Hopson SD; Moretz C; Annavarapu S; Burslem K; Renda A; Kaila S
Int J Chron Obstruct Pulmon Dis; 2017; 12():735-744. PubMed ID: 28260880
[TBL] [Abstract][Full Text] [Related]
32. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis.
Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
Clinicoecon Outcomes Res; 2020; 12():369-377. PubMed ID: 32765022
[TBL] [Abstract][Full Text] [Related]
33. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
34. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Foster SA; Hoyt M; Ye W; Mason O; Ford JH
Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
[TBL] [Abstract][Full Text] [Related]
35. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.
Exuzides A; To TM; Abbass IM; Ta JT; Patel AM; Surinach A; Fuller RLM; Luo J
J Med Econ; 2022; 25(1):722-729. PubMed ID: 35608039
[TBL] [Abstract][Full Text] [Related]
36. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
[TBL] [Abstract][Full Text] [Related]
37. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
Hudesman DP; Chakravarty SD; Emond B; Ellis LA; Lefebvre P; Sadik K; Scher JU
BMC Rheumatol; 2020; 4():16. PubMed ID: 32266326
[TBL] [Abstract][Full Text] [Related]
38. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
[TBL] [Abstract][Full Text] [Related]
39. Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan.
Miyazaki C; Masuda J; Rodriguez-Rey MD; Stelmaszuk MN; Freilich J; Tsai PI; Saeki H
J Dermatolog Treat; 2024 Dec; 35(1):2299598. PubMed ID: 38317525
[TBL] [Abstract][Full Text] [Related]
40. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
